- Home
- SBR vs TRVI Comparison
SBR vs TRVI Comparison
Compare SBR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- TRVI
- Stock Information
- Founded
- SBR 1982
- TRVI 2011
- Country
- SBR United States
- TRVI United States
- Employees
- SBR N/A
- TRVI N/A
- Industry
- SBR Oil & Gas Production
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SBR Energy
- TRVI Health Care
- Exchange
- SBR Nasdaq
- TRVI Nasdaq
- Market Cap
- SBR 1.1B
- TRVI 1.1B
- IPO Year
- SBR N/A
- TRVI 2019
- Fundamental
- Price
- SBR $71.40
- TRVI $11.37
- Analyst Decision
- SBR
- TRVI Strong Buy
- Analyst Count
- SBR 0
- TRVI 9
- Target Price
- SBR N/A
- TRVI $20.72
- AVG Volume (30 Days)
- SBR 50.5K
- TRVI 1.6M
- Earning Date
- SBR 01-01-0001
- TRVI 11-10-2025
- Dividend Yield
- SBR 7.55%
- TRVI N/A
- EPS Growth
- SBR N/A
- TRVI N/A
- EPS
- SBR 5.05
- TRVI N/A
- Revenue
- SBR $77,682,730.00
- TRVI N/A
- Revenue This Year
- SBR N/A
- TRVI N/A
- Revenue Next Year
- SBR N/A
- TRVI N/A
- P/E Ratio
- SBR $14.10
- TRVI N/A
- Revenue Growth
- SBR N/A
- TRVI N/A
- 52 Week Low
- SBR $58.25
- TRVI $2.36
- 52 Week High
- SBR $84.39
- TRVI $11.18
- Technical
- Relative Strength Index (RSI)
- SBR 50.76
- TRVI 72.03
- Support Level
- SBR $69.04
- TRVI $10.30
- Resistance Level
- SBR $72.98
- TRVI $10.90
- Average True Range (ATR)
- SBR 1.70
- TRVI 0.53
- MACD
- SBR 0.44
- TRVI -0.01
- Stochastic Oscillator
- SBR 77.04
- TRVI 97.07
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.